ACC and AHA release updated cholesterol management guidelines

The American College of Cardiology and American Heart Association have issued new guidelines on cholesterol screening and management, urging earlier testing and personalized risk assessments. The recommendations, presented on March 28 in New Orleans, emphasize lowering LDL cholesterol and incorporating genetic factors like lipoprotein(a). A new risk calculator aims to predict heart disease over longer periods.

The guidelines, the first update since 2018, were published in the Journal of the American College of Cardiology and Circulation. They were unveiled at the American College of Cardiology's 75th Annual Scientific Session in New Orleans. Roger S. Blumenthal, chair of the writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, stated, 'We know that lower LDL cholesterol levels are better when it comes to reducing the risk of heart attacks, strokes and congestive heart failure.' The guidance stresses lifestyle changes as the foundation, noting that 80% to 90% of cardiovascular disease links to modifiable factors like diet, exercise, and weight control. About one in four U.S. adults has elevated LDL cholesterol, which contributes to atherosclerosis and potential heart events. Doctors are now advised to screen earlier, such as from age 9 for those with familial hypercholesterolemia, and perform a one-time Lp(a) test, which elevates risk by 40% at certain levels. The new PREVENT calculator estimates 10- and 30-year risks starting at age 30, drawing from data on 6.6 million people and including kidney function and blood sugar. Seth Martin, a cardiologist on the committee, said, 'Shifting the paradigm toward proactive prevention strategies earlier in life can meaningfully change the trajectory of cardiovascular disease.' For treatment, optimal LDL targets range from below 100 mg/dL for low-risk individuals to under 55 mg/dL for high-risk ones, with options like statins, ezetimibe, and PCSK9 inhibitors. Risk enhancers such as coronary artery calcium scans and inflammation markers help tailor plans.

Articoli correlati

Illustration of Mayo Clinic study revealing 90% gap in genetic screening for familial hypercholesterolemia, featuring lab scientists, DNA data, heart plaque model, and screening call-to-action.
Immagine generata dall'IA

Mayo Clinic study finds major gaps in genetic screening for inherited high cholesterol

Riportato dall'IA Immagine generata dall'IA Verificato

A large Mayo Clinic study reports that current guidelines fail to detect nearly 90% of people with familial hypercholesterolemia, a common inherited cause of dangerously high cholesterol and early heart disease. Researchers analyzed exome data from more than 84,000 participants and found that most would not have been selected for standard genetic testing. Expanding routine DNA screening, they say, could help identify at-risk individuals earlier and prevent severe cardiovascular outcomes.

A large-scale genetic analysis of about 1.09 million people suggests that lifelong, genetically lower cholesterol—specifically non‑HDL cholesterol—is associated with substantially reduced dementia risk. Using Mendelian randomization to emulate the effects of cholesterol‑lowering drug targets such as those for statins (HMGCR) and ezetimibe (NPC1L1), the study found up to an approximately 80% lower risk per 1 mmol/L reduction for some targets. ([research-information.bris.ac.uk](https://research-information.bris.ac.uk/en/publications/cholesterollowering-drug-targets-reduce-risk-of-dementia-mendelia?utm_source=openai))

Riportato dall'IA Verificato

A Mount Sinai–led study finds that commonly used heart-attack risk calculators and symptom-based screening fail to identify nearly half of people who will soon experience a first heart attack. The brief report, published November 21 in JACC: Advances, underscores limitations in current prevention strategies and argues for earlier imaging to detect silent plaque.

Researchers at Karolinska Institutet have found that even kidney test results within the normal range can signal future chronic kidney disease if they are low for a person's age. The study, based on data from over 1.1 million adults in Stockholm, introduces reference charts and an online tool to help doctors identify at-risk patients earlier. This could prevent serious damage, as kidney disease often goes undetected until half of kidney function is lost.

Riportato dall'IA

Uno studio svedese suggerisce che consumare più formaggio ad alto contenuto di grassi potrebbe ridurre il rischio di demenza del 13%, sulla base di dati di quasi 30.000 persone seguite per 25 anni. Tuttavia, gli esperti avvertono che si tratta di un'analisi osservazionale senza prova di causalità. I critici evidenziano potenziali confonditori e l'importanza di fattori come la pressione sanguigna e il controllo del peso.

A large review of randomized trials indicates that statins do not cause the majority of side effects listed on their labels. Symptoms such as memory problems and depression occurred at similar rates in statin users and those taking placebos. The findings aim to address concerns that have led some patients to avoid these heart-protecting medications.

Riportato dall'IA Verificato

An analysis of more than 63,000 French adults from the long-running NutriNet-Santé cohort found that plant-based diets built around minimally processed, nutritionally high-quality foods were associated with about a 40% lower risk of cardiovascular disease, while diets heavy in ultra-processed plant products could erase this benefit and were tied to substantially higher risk, according to researchers from INRAE and partner institutions.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta